U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07223697) titled 'A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis' on Oct. 30.
Brief Summary: This study will assess long-term safety and efficacy of Afimkibart (also known as RO7790121) in participants with Atopic Dermatitis (AD) who participated in previous afimkibart clinical trials.
Study Start Date: Dec. 16
Study Type: INTERVENTIONAL
Condition:
Atopic Dermatitis
Intervention:
DRUG: Afimkibart
Afimkibart will be administered as per the schedule defined in the protocol.
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Hoffmann-La Roche
Published by HT Digital ...